GlassScriptPhysician profile
Dalia Lawandy
NPI 1891179198
$1,909.39
in general payments reported to CMS, 2019-2025
23 companies · $118 in 2025
The $118 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $510 · 2020: $177 · 2021: $320 · 2022: $342 · 2023: $335 · 2024: $108 · 2025: $118.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $561.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $561.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $656.14 | 2019-2025 | |
| Novo Nordisk INC | $375.80 | 2019-2025 | Ozempic, Rybelsus |
| Amgen INC. | $150.68 | 2019-2021 | |
| Lilly USA, LLC | $97.00 | 2019-2023 | Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $94.87 | 2019-2023 | |
| Allergan, INC. | $70.06 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $60.49 | 2021-2023 | Xigduo |
| Pfizer INC. | $59.81 | 2019-2024 | |
| Abbott Laboratories | $57.76 | 2023-2025 | Freestyle Libre 3 |
| Takeda Pharmaceuticals U.S.A., INC. | $46.37 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $37.97 | 2019-2022 | |
| Glaxosmithkline, LLC. | $34.04 | 2019-2021 | |
| Boston Scientific Corporation | $24.96 | 2024 | Watchman Access System |
| Upsher-Smith Laboratories LLC | $20.30 | 2020 | |
| Janssen Pharmaceuticals, INC | $20.27 | 2023 | Invega Sustenna |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $16.90 | 2025 | Inspire |
| Genentech USA, INC. | $14.74 | 2019 | |
| Sanofi-Aventis U.S. LLC | $13.97 | 2023 | |
| Astellas Pharma US INC | $13.64 | 2019 | |
| Nestle Healthcare Nutrition INC. | $12.79 | 2021 | |
| Jazz Pharmaceuticals INC. | $11.88 | 2022 | |
| Promius Pharma LLC | $11.30 | 2019 | |
| Phathom Pharmaceuticals, INC. | $7.65 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dalia Lawandy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.